Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study.
- Published In:
- Journal of hepatology, 82(1), 7-17 (2025)
- Authors:
- Harrison, Stephen A(2), Browne, Sarah K, Suschak, John J, Tomah, Shaheen, Gutierrez, Julio A, Yang, Jay, Roberts, M Scot, Harris, M Scott
- Database ID:
- RPEP-11307
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-11307APA
Harrison, Stephen A; Browne, Sarah K; Suschak, John J; Tomah, Shaheen; Gutierrez, Julio A; Yang, Jay; Roberts, M Scot; Harris, M Scott. (2025). Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study.. Journal of hepatology, 82(1), 7-17. https://doi.org/10.1016/j.jhep.2024.07.006
MLA
Harrison, Stephen A, et al. "Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study.." Journal of hepatology, 2025. https://doi.org/10.1016/j.jhep.2024.07.006
RethinkPeptides
RethinkPeptides Research Database. "Effect of pemvidutide, a GLP-1/glucagon dual receptor agonis..." RPEP-11307. Retrieved from https://rethinkpeptides.com/research/harrison-2025-effect-of-pemvidutide-a
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.